Amkay Products (544169)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 15.62 is reasonable, and PEG of 0.85 suggests growth is not yet fully priced in.
• ROCE of 16.88% indicates decent capital efficiency.
• Sales growth of 28.98% shows healthy demand for the products.
• Piotroski F-Score of 7/9 points to sound financial health.
• Latest quarter was profitable: sales of ₹23 Cr and net profit of ₹2 Cr.

Concerns

• Profit growth of 7.65% lags far behind sales growth of 28.98%, indicating margin pressure.
• Dividend yield is zero, so investors get no cash return while waiting.
• Data on debt/equity, book value, and promoter holding is unavailable, creating transparency concerns.
• Market cap of only ₹54 Cr leaves limited room for institutional validation and makes the stock more vulnerable to volatility.

AI Analysis

At ₹62.80, Amkay Products carries a market cap of only ₹54 crore and a P/E of 15.62. That is not an expensive multiple for a medical equipment supplier. I value small, comprehensible businesses if they earn good returns on capital without excessive leverage. The 16.88% ROCE is respectable; it tells me capital is being deployed reasonably. The Piotroski F-Score of 7 out of 9 adds some comfort on financial health, though I lack details on debt, book value, and promoter holding. The business has energy: sales grew 28.98%, but profit only rose 7.65%. That discrepancy bothers me. In a good business, profit should at least keep pace with sales. Here, margins are being squeezed, or costs are rising faster than revenue. I would rather own an average company at a great price than a great company at a mediocre price, but I first need evidence of a moat. I do not see it in these numbers. Medical supplies can be competitive, and many products are commoditised. The PEG ratio of 0.85 looks attractive, but it is only meaningful if the growth is durable. The latest quarter shows sales of ₹23 crore and net profit of ₹2 crore, so the scale is small. No dividend means I receive nothing while I wait; my return depends entirely on reinvestment and eventual market recognition. That reduces my margin of safety. If the company can convert its strong top-line growth into bottom-line growth, this could become a decent small grower. At present, it is a fast grower in sales but not yet in earnings. I would wait for proof of margin stability, or demand a bigger discount before committing any capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer